☰

Madeline Luth - Publications

Affiliations: 
2016- Pediatrics University of California, San Diego, La Jolla, CA 
Tree Info Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Luth MR, Godinez-Macias KP, Chen D, Okombo J, Thathy V, Cheng X, Daggupati S, Davies H, Dhingra SK, Economy JM, Edgar RCS, Gomez-Lorenzo MG, Istvan ES, Jado JC, LaMonte GM, et al. Systematic in vitro evolution in reveals key determinants of drug resistance. Science (New York, N.Y.). 386: eadk9893. PMID 39607932 DOI: 10.1126/science.adk9893  0.765
2024 Xie SC, Wang Y, Morton CJ, Metcalfe RD, Dogovski C, Pasaje CFA, Dunn E, Luth MR, Kumpornsin K, Istvan ES, Park JS, Fairhurst KJ, Ketprasit N, Yeo T, Yildirim O, et al. Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase. Nature Communications. 15: 937. PMID 38297033 DOI: 10.1038/s41467-024-45224-z  0.669
2023 Collins JE, Lee JW, Rocamora F, Saggu GS, Wendt KL, Pasaje CFA, Smick S, Santos NM, Paes R, Jiang T, Mittal N, Luth MR, Chin T, Chang H, McLellan JL, et al. Antiplasmodial peptaibols act through membrane directed mechanisms. Cell Chemical Biology. PMID 37995692 DOI: 10.1016/j.chembiol.2023.10.025  0.593
2023 Mandt REK, Luth MR, Tye MA, Mazitschek R, Ottilie S, Winzeler EA, Lafuente-Monasterio MJ, Gamo FJ, Wirth DF, Lukens AK. Diverse evolutionary pathways challenge the use of collateral sensitivity as a strategy to suppress resistance. Elife. 12. PMID 37737220 DOI: 10.7554/eLife.85023  0.676
2023 Tilley L, Xie S, Wang Y, Morton C, Metcalfe R, Dogovski C, Pasaje CF, Dunn E, Luth M, Kumpornsin K, Istvan E, Park J, Fairhurst K, Yeo T, Yildirim O, et al. Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase. Research Square. PMID 37546892 DOI: 10.21203/rs.3.rs-3198291/v1  0.669
2023 Kümpornsin K, Kochakarn T, Yeo T, Okombo J, Luth MR, Hoshizaki J, Rawat M, Pearson RD, Schindler KA, Mok S, Park H, Uhlemann AC, Jana GP, Maity BC, Laleu B, et al. Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum. Nature Communications. 14: 3059. PMID 37244916 DOI: 10.1038/s41467-023-38774-1  0.655
2023 Armstrong JF, Campo B, Alexander SPH, Arendse LB, Cheng X, Davenport AP, Faccenda E, Fidock DA, Godinez-Macias KP, Harding SD, Kato N, Lee MCS, Luth MR, Mazitschek R, Mittal N, et al. Advances in Malaria Pharmacology and the online Guide to MALARIA PHARMACOLOGY: IUPHAR Review X. British Journal of Pharmacology. PMID 37197802 DOI: 10.1111/bph.16144  0.475
2023 Bohmer MJ, Wang J, Istvan ES, Luth MR, Collins JE, Huttlin EL, Wang L, Mittal N, Hao M, Kwiatkowski NP, Gygi SP, Chakrabarti R, Deng X, Goldberg DE, Winzeler EA, et al. Human Polo-like Kinase Inhibitors as Antiplasmodials. Acs Infectious Diseases. PMID 36919909 DOI: 10.1021/acsinfecdis.3c00025  0.588
2023 Istvan ES, Guerra F, Abraham M, Huang KS, Rocamora F, Zhao H, Xu L, Pasaje C, Kumpornsin K, Luth MR, Cui H, Yang T, Palomo Diaz S, Gomez-Lorenzo MG, Qahash T, et al. Cytoplasmic isoleucyl tRNA synthetase as an attractive multistage antimalarial drug target. Science Translational Medicine. 15: eadc9249. PMID 36888694 DOI: 10.1126/scitranslmed.adc9249  0.827
2022 Arendse LB, Murithi JM, Qahash T, Pasaje CFA, Godoy LC, Dey S, Gibhard L, Ghidelli-Disse S, Drewes G, Bantscheff M, Lafuente-Monasterio MJ, Fienberg S, Wambua L, Gachuhi S, Coertzen D, ... ... Luth MR, et al. The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple kinases and life cycle stages. Science Translational Medicine. 14: eabo7219. PMID 36260689 DOI: 10.1126/scitranslmed.abo7219  0.678
2022 Tye MA, Payne NC, Johansson C, Singh K, Santos SA, Fagbami L, Pant A, Sylvester K, Luth MR, Marques S, Whitman M, Mota MM, Winzeler EA, Lukens AK, Derbyshire ER, et al. Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. Nature Communications. 13: 4976. PMID 36008486 DOI: 10.1038/s41467-022-32630-4  0.678
2022 Xie SC, Metcalfe RD, Dunn E, Morton CJ, Huang SC, Puhalovich T, Du Y, Wittlin S, Nie S, Luth MR, Ma L, Kim MS, Pasaje CFA, Kumpornsin K, Giannangelo C, et al. Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy. Science (New York, N.Y.). 376: 1074-1079. PMID 35653481 DOI: 10.1126/science.abn0611  0.593
2022 Ottilie S, Luth MR, Hellemann E, Goldgof GM, Vigil E, Kumar P, Cheung AL, Song M, Godinez-Macias KP, Carolino K, Yang J, Lopez G, Abraham M, Tarsio M, LeBlanc E, et al. Adaptive laboratory evolution in S. cerevisiae highlights role of transcription factors in fungal xenobiotic resistance. Communications Biology. 5: 128. PMID 35149760 DOI: 10.1038/s42003-022-03076-7  0.763
2021 Ellis KM, Lucantoni L, Chavchich M, Abraham M, De Paoli A, Luth MR, Zeeman AM, Delves MJ, Terán FS, Straschil U, Baum J, Kocken CH, Ralph SA, Winzeler EA, Avery VM, et al. The novel bis-1,2,4-triazine MIPS-0004373 demonstrates rapid and potent activity against all blood stages of the malaria parasite. Antimicrobial Agents and Chemotherapy. AAC0031121. PMID 34460304 DOI: 10.1128/AAC.00311-21  0.809
2021 Summers RL, Pasaje CFA, Pisco JP, Striepen J, Luth MR, Kumpornsin K, Carpenter EF, Munro JT, Lin, Plater A, Punekar AS, Shepherd AM, Shepherd SM, Vanaerschot M, Murithi JM, et al. Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. Cell Chemical Biology. PMID 34348113 DOI: 10.1016/j.chembiol.2021.07.010  0.723
2021 Rocamora F, Gupta P, Istvan ES, Luth MR, Carpenter EF, Kümpornsin K, Sasaki E, Calla J, Mittal N, Carolino K, Owen E, Llinás M, Ottilie S, Goldberg DE, Lee MCS, et al. PfMFR3: A Multidrug-Resistant Modulator in . Acs Infectious Diseases. PMID 33715347 DOI: 10.1021/acsinfecdis.0c00676  0.802
2020 Luth MR, Winzeler EA. SnapShot: Antimalarial Drugs. Cell. 183: 554-554.e1. PMID 33064992 DOI: 10.1016/j.cell.2020.09.006  0.667
2020 LaMonte GM, Rocamora F, Marapana DS, Gnädig NF, Ottilie S, Luth MR, Worgall TS, Goldgof GM, Mohunlal R, Santha Kumar TR, Thompson JK, Vigil E, Yang J, Hutson D, Johnson T, et al. Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway. Nature Communications. 11: 1780. PMID 32286267 DOI: 10.1038/S41467-020-15440-4  0.687
2020 Abraham M, Gagaring K, Marino ML, Vanaerschot M, Plouffe D, Calla J, Godinez Macias K, Du A, Wree M, Antonova-Koch Y, Eribez K, Luth MR, Ottilie S, Fidock DA, McNamara C, et al. Probing the Open Global Health Chemical Diversity Library for multistage-active starting points for next-generation antimalarials. Acs Infectious Diseases. PMID 32078764 DOI: 10.1021/Acsinfecdis.9B00482  0.715
2019 Rosenberg A, Luth MR, Winzeler EA, Behnke M, Sibley LD. Evolution of resistance in vitro reveals mechanisms of artemisinin activity in . Proceedings of the National Academy of Sciences of the United States of America. PMID 31806760 DOI: 10.1073/Pnas.1914732116  0.664
2019 Mandt REK, Lafuente-Monasterio MJ, Sakata-Kato T, Luth MR, Segura D, Pablos-Tanarro A, Viera S, Magan N, Ottilie S, Winzeler EA, Lukens AK, Gamo FJ, Wirth DF. In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model. Science Translational Medicine. 11. PMID 31801884 DOI: 10.1126/Scitranslmed.Aav1636  0.651
2019 Stokes BH, Yoo E, Murithi JM, Luth MR, Afanasyev P, da Fonseca PCA, Winzeler EA, Ng CL, Bogyo M, Fidock DA. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. Plos Pathogens. 15: e1007722. PMID 31170268 DOI: 10.1371/Journal.Ppat.1007722  0.661
2018 Antonova-Koch Y, Meister S, Abraham M, Luth MR, Ottilie S, Lukens AK, Sakata-Kato T, Vanaerschot M, Owen E, Jado Rodriguez JC, Maher SP, Calla J, Plouffe D, Zhong Y, Chen K, et al. Open-source discovery of chemical leads for next-generation chemoprotective antimalarials. Science (New York, N.Y.). 362. PMID 30523084 DOI: 10.1126/Science.Aat9446  0.725
2018 Xie SC, Gillett DL, Spillman NJ, Tsu C, Luth MR, Ottilie S, Duffy S, Gould A, Hales P, Seager BA, Charron CL, Bruzzese F, Yang X, Zhao X, Huang SC, et al. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome. Journal of Medicinal Chemistry. PMID 30373366 DOI: 10.1021/Acs.Jmedchem.8B01161  0.668
2018 Luth MR, Gupta P, Ottilie S, Winzeler EA. Using in Vitro Evolution and Whole Genome Analysis (IVIEWGA) to discover next generation targets for antimalarial drug discovery. Acs Infectious Diseases. PMID 29451780 DOI: 10.1021/Acsinfecdis.7B00276  0.608
2017 Debnath A, Calvet CM, Jennings G, Zhou W, Aksenov A, Luth MR, Abagyan R, Nes WD, McKerrow JH, Podust LM. CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM). Plos Neglected Tropical Diseases. 11: e0006104. PMID 29284029 DOI: 10.1371/Journal.Pntd.0006104  0.312
Show low-probability matches.